Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748130 | 0.96 | ESR1 (0.92) | ESR1 | |
| SCHEMBL21266026 | 0.94 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL30612551 | 0.94 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL21248003 | 0.94 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL21248000 | 0.94 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL21265985 | 0.94 | ESR1 (1.00) | ESR1 | |
| SCHEMBL30612569 | 0.94 | ESR1 (1.00) | ESR1 | |
| SCHEMBL26267913 | 0.93 | ESR1 (0.87) | ESR1 | |
| SCHEMBL26267712 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL20747903 | 0.91 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-05-13 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3749654-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | The Board of Trustees of the University of Illinois (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2019157020-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019157020-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | ESR1, GPER1, CYP19A1 | ESR1 1/4885ESR2 5/4885 |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | ESR1, GPER1, CYP19A1 | ESR1 1/4885ESR2 5/4885 |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, CYP19A1 | ESR1 1/4885ESR2 5/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, CYP19A1 | ESR1 1/4885ESR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.